286 related articles for article (PubMed ID: 24892807)
1. CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.
Herrmann A; Priceman SJ; Swiderski P; Kujawski M; Xin H; Cherryholmes GA; Zhang W; Zhang C; Lahtz C; Kowolik C; Forman SJ; Kortylewski M; Yu H
J Clin Invest; 2014 Jul; 124(7):2977-87. PubMed ID: 24892807
[TBL] [Abstract][Full Text] [Related]
2. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.
Kujawski M; Zhang C; Herrmann A; Reckamp K; Scuto A; Jensen M; Deng J; Forman S; Figlin R; Yu H
Cancer Res; 2010 Dec; 70(23):9599-610. PubMed ID: 21118964
[TBL] [Abstract][Full Text] [Related]
3. Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation.
Li SY; Liu Y; Xu CF; Shen S; Sun R; Du XJ; Xia JX; Zhu YH; Wang J
J Control Release; 2016 Jun; 231():17-28. PubMed ID: 26829099
[TBL] [Abstract][Full Text] [Related]
4. Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells.
Herrmann A; Kortylewski M; Kujawski M; Zhang C; Reckamp K; Armstrong B; Wang L; Kowolik C; Deng J; Figlin R; Yu H
Cancer Res; 2010 Oct; 70(19):7455-64. PubMed ID: 20841481
[TBL] [Abstract][Full Text] [Related]
5. Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity.
Berezhnoy A; Castro I; Levay A; Malek TR; Gilboa E
J Clin Invest; 2014 Jan; 124(1):188-97. PubMed ID: 24292708
[TBL] [Abstract][Full Text] [Related]
6. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.
Ahern E; Harjunpää H; Barkauskas D; Allen S; Takeda K; Yagita H; Wyld D; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2017 Oct; 23(19):5789-5801. PubMed ID: 28634284
[No Abstract] [Full Text] [Related]
7. Cell-extrinsic CTLA4-mediated regulation of dendritic cell maturation depends on STAT3.
Kowalczyk A; D'Souza CA; Zhang L
Eur J Immunol; 2014 Apr; 44(4):1143-55. PubMed ID: 24338929
[TBL] [Abstract][Full Text] [Related]
8. Enhanced cytotoxic T lymphocytes recruitment targeting tumor vasculatures by endoglin aptamer and IP-10 plasmid presenting liposome-based nanocarriers.
Yang X; Zhao J; Duan S; Hou X; Li X; Hu Z; Tang Z; Mo F; Lu X
Theranostics; 2019; 9(14):4066-4083. PubMed ID: 31281532
[No Abstract] [Full Text] [Related]
9. Targeting
Le PT; Ha N; Tran NK; Newman AG; Esselen KM; Dalrymple JL; Schmelz EM; Bhandoola A; Xue HH; Singh PB; Thai TH
Front Immunol; 2021; 12():738958. PubMed ID: 34721405
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors.
Manuel ER; Blache CA; Paquette R; Kaltcheva TI; Ishizaki H; Ellenhorn JD; Hensel M; Metelitsa L; Diamond DJ
Cancer Res; 2011 Jun; 71(12):4183-91. PubMed ID: 21527558
[TBL] [Abstract][Full Text] [Related]
11. CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity.
Herrmann A; Lahtz C; Nagao T; Song JY; Chan WC; Lee H; Yue C; Look T; Mülfarth R; Li W; Jenkins K; Williams J; Budde LE; Forman S; Kwak L; Blankenstein T; Yu H
Cancer Res; 2017 Sep; 77(18):5118-5128. PubMed ID: 28716895
[TBL] [Abstract][Full Text] [Related]
12. B cell-Derived IL35 Drives STAT3-Dependent CD8
Mirlekar B; Michaud D; Lee SJ; Kren NP; Harris C; Greene K; Goldman EC; Gupta GP; Fields RC; Hawkins WG; DeNardo DG; Rashid NU; Yeh JJ; McRee AJ; Vincent BG; Vignali DAA; Pylayeva-Gupta Y
Cancer Immunol Res; 2020 Mar; 8(3):292-308. PubMed ID: 32024640
[TBL] [Abstract][Full Text] [Related]
13. Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation.
Schwartz AL; Nath PR; Allgauer M; Lessey-Morillon EC; Sipes JM; Ridnour LA; Morillon Ii YM; Yu Z; Restifo NP; Roberts DD
Cancer Immunol Immunother; 2019 Nov; 68(11):1805-1817. PubMed ID: 31628526
[TBL] [Abstract][Full Text] [Related]
14. The aptamer-siRNA conjugates: reprogramming T cells for cancer therapy.
Sakib Hossain DM; Duttagupta P; Kortylewski M
Ther Deliv; 2015 Jan; 6(1):1-4. PubMed ID: 25565435
[No Abstract] [Full Text] [Related]
15. RORγt-Expressing Tregs Drive the Growth of Colitis-Associated Colorectal Cancer by Controlling IL6 in Dendritic Cells.
Rizzo A; Di Giovangiulio M; Stolfi C; Franzè E; Fehling HJ; Carsetti R; Giorda E; Colantoni A; Ortenzi A; Rugge M; Mescoli C; Monteleone G; Fantini MC
Cancer Immunol Res; 2018 Sep; 6(9):1082-1092. PubMed ID: 29991500
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.
Molavi O; Ma Z; Hamdy S; Lai R; Lavasanifar A; Samuel J
Immunol Cell Biol; 2008; 86(6):506-14. PubMed ID: 18392040
[TBL] [Abstract][Full Text] [Related]
17. Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity.
Hossain DM; Dos Santos C; Zhang Q; Kozlowska A; Liu H; Gao C; Moreira D; Swiderski P; Jozwiak A; Kline J; Forman S; Bhatia R; Kuo YH; Kortylewski M
Blood; 2014 Jan; 123(1):15-25. PubMed ID: 24169824
[TBL] [Abstract][Full Text] [Related]
18. Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model.
Hinterleitner R; Gruber T; Pfeifhofer-Obermair C; Lutz-Nicoladoni C; Tzankov A; Schuster M; Penninger JM; Loibner H; Lametschwandtner G; Wolf D; Baier G
PLoS One; 2012; 7(9):e44295. PubMed ID: 22962608
[TBL] [Abstract][Full Text] [Related]
19. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
[TBL] [Abstract][Full Text] [Related]
20. STAT3 in CD8+ T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 Axis.
Yue C; Shen S; Deng J; Priceman SJ; Li W; Huang A; Yu H
Cancer Immunol Res; 2015 Aug; 3(8):864-870. PubMed ID: 26025380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
